BQ-123

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
BQ-123
Accession Number
DB12054
Type
Small Molecule
Groups
Investigational
Description

BQ-123 has been investigated for the basic science and treatment of Coronary Artery Disease, Aorto-coronary Bypass Grafting, and ST-Elevation Myocardial Infarction.

Structure
Thumb
Synonyms
Not Available
External IDs
BQ123
Product Ingredients
IngredientUNIICASInChI Key
Bq 123 Sodium05427HSQ1I136655-57-7FLIKEIGEOXCRRG-JKNHBXRPSA-M
Categories
UNII
S2A8YZM151
CAS number
136553-81-6
Weight
Average: 610.712
Monoisotopic: 610.311497716
Chemical Formula
C31H42N6O7
InChI Key
VYCMAAOURFJIHD-PJNXIOHISA-N
InChI
InChI=1S/C31H42N6O7/c1-16(2)12-21-27(40)33-22(13-18-15-32-20-9-6-5-8-19(18)20)28(41)35-23(14-25(38)39)31(44)37-11-7-10-24(37)29(42)36-26(17(3)4)30(43)34-21/h5-6,8-9,15-17,21-24,26,32H,7,10-14H2,1-4H3,(H,33,40)(H,34,43)(H,35,41)(H,36,42)(H,38,39)/t21-,22+,23+,24-,26+/m0/s1
IUPAC Name
2-[(3R,6S,9R,12R,17aS)-9-[(1H-indol-3-yl)methyl]-6-(2-methylpropyl)-1,4,7,10,13-pentaoxo-3-(propan-2-yl)-hexadecahydro-1H-pyrrolo[1,2-a]1,4,7,10,13-pentaazacyclopentadecan-12-yl]acetic acid
SMILES
CC(C)C[[email protected]@H]1NC(=O)[[email protected]](NC(=O)[[email protected]@H]2CCCN2C(=O)[[email protected]@H](CC(O)=O)NC(=O)[[email protected]@H](CC2=CNC3=CC=CC=C23)NC1=O)C(C)C

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of BQ-123.Experimental
AcebutololAcebutolol may increase the hypotensive activities of BQ-123.Approved, Investigational
AcemetacinThe therapeutic efficacy of BQ-123 can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AlfuzosinAlfuzosin may increase the hypotensive activities of BQ-123.Approved, Investigational
AliskirenAliskiren may increase the hypotensive activities of BQ-123.Approved, Investigational
AlprenololAlprenolol may increase the hypotensive activities of BQ-123.Approved, Withdrawn
AmbrisentanBQ-123 may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineBQ-123 may increase the hypotensive activities of Amifostine.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of BQ-123.Approved
AmphetamineAmphetamine may increase the hypotensive activities of BQ-123.Approved, Illicit, Investigational
AtenololAtenolol may increase the hypotensive activities of BQ-123.Approved
AvanafilAvanafil may increase the antihypertensive activities of BQ-123.Approved
BarnidipineBQ-123 may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of BQ-123.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of BQ-123.Approved
BenmoxinBenmoxin may increase the hypotensive activities of BQ-123.Withdrawn
BepridilBepridil may increase the hypotensive activities of BQ-123.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of BQ-123.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of BQ-123.Approved
BietaserpineBietaserpine may increase the hypotensive activities of BQ-123.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of BQ-123.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of BQ-123.Approved
BosentanBosentan may increase the hypotensive activities of BQ-123.Approved, Investigational
BretyliumBretylium may increase the hypotensive activities of BQ-123.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of BQ-123.Approved
BrofaromineBrofaromine may increase the hypotensive activities of BQ-123.Experimental
BupranololBupranolol may increase the hypotensive activities of BQ-123.Approved
CadralazineCadralazine may increase the hypotensive activities of BQ-123.Experimental
CafedrineBQ-123 may increase the hypotensive activities of Cafedrine.Investigational
CandesartanBQ-123 may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of BQ-123.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of BQ-123.Experimental
CaptoprilCaptopril may increase the hypotensive activities of BQ-123.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of BQ-123.Withdrawn
CarteololCarteolol may increase the hypotensive activities of BQ-123.Approved
CarvedilolCarvedilol may increase the hypotensive activities of BQ-123.Approved, Investigational
CeliprololCeliprolol may increase the hypotensive activities of BQ-123.Approved, Investigational
ChlorothiazideChlorothiazide may increase the hypotensive activities of BQ-123.Approved, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of BQ-123.Approved
CicletanineBQ-123 may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilCilazapril may increase the hypotensive activities of BQ-123.Approved
ClonidineClonidine may increase the hypotensive activities of BQ-123.Approved
CloranololBQ-123 may increase the hypotensive activities of Cloranolol.Experimental
CryptenamineCryptenamine may increase the hypotensive activities of BQ-123.Approved
CyclopenthiazideBQ-123 may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideCyclothiazide may increase the hypotensive activities of BQ-123.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of BQ-123.Approved, Investigational
DelaprilBQ-123 may increase the hypotensive activities of Delapril.Experimental
DeserpidineBQ-123 may increase the hypotensive activities of Deserpidine.Approved
DiazoxideDiazoxide may increase the hypotensive activities of BQ-123.Approved
DiethylnorspermineDiethylnorspermine may increase the hypotensive activities of BQ-123.Investigational
DihydralazineDihydralazine may increase the hypotensive activities of BQ-123.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of BQ-123.Approved, Investigational
DorzolamideDorzolamide may increase the hypotensive activities of BQ-123.Approved
DoxazosinDoxazosin may increase the hypotensive activities of BQ-123.Approved
EfonidipineEfonidipine may increase the hypotensive activities of BQ-123.Approved, Investigational
EnalaprilEnalapril may increase the hypotensive activities of BQ-123.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the hypotensive activities of BQ-123.Approved
EndralazineEndralazine may increase the hypotensive activities of BQ-123.Experimental
EpanololBQ-123 may increase the hypotensive activities of Epanolol.Experimental
EpoprostenolEpoprostenol may increase the hypotensive activities of BQ-123.Approved
EprosartanEprosartan may increase the hypotensive activities of BQ-123.Approved
FelodipineFelodipine may increase the hypotensive activities of BQ-123.Approved, Investigational
FenoldopamFenoldopam may increase the hypotensive activities of BQ-123.Approved
Ferulic acidFerulic acid may increase the hypotensive activities of BQ-123.Experimental
FosinoprilFosinopril may increase the hypotensive activities of BQ-123.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of BQ-123.Approved, Investigational, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of BQ-123.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of BQ-123.Approved
GuanazodineBQ-123 may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of BQ-123.Approved
GuanfacineGuanfacine may increase the hypotensive activities of BQ-123.Approved, Investigational
GuanoclorBQ-123 may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzBQ-123 may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanBQ-123 may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of BQ-123.Experimental
HexamethoniumHexamethonium may increase the hypotensive activities of BQ-123.Experimental
HydracarbazineHydracarbazine may increase the hypotensive activities of BQ-123.Experimental
HydralazineHydralazine may increase the hypotensive activities of BQ-123.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of BQ-123.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of BQ-123.Approved, Investigational
IloprostIloprost may increase the hypotensive activities of BQ-123.Approved, Investigational
ImidaprilImidapril may increase the hypotensive activities of BQ-123.Investigational
IndapamideIndapamide may increase the hypotensive activities of BQ-123.Approved
IndenololIndenolol may increase the hypotensive activities of BQ-123.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of BQ-123.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of BQ-123.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of BQ-123.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of BQ-123.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of BQ-123.Approved
IsradipineIsradipine may increase the hypotensive activities of BQ-123.Approved, Investigational
KetanserinKetanserin may increase the hypotensive activities of BQ-123.Investigational
LabetalolLabetalol may increase the hypotensive activities of BQ-123.Approved
LacidipineLacidipine may increase the hypotensive activities of BQ-123.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of BQ-123.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of BQ-123.Approved, Investigational
LinsidomineBQ-123 may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of BQ-123.Approved, Investigational
LofexidineLofexidine may increase the hypotensive activities of BQ-123.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of BQ-123.Approved
MacitentanBQ-123 may increase the hypotensive activities of Macitentan.Approved
ManidipineManidipine may increase the hypotensive activities of BQ-123.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of BQ-123.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of BQ-123.Approved, Investigational
MethoserpidineBQ-123 may increase the hypotensive activities of Methoserpidine.Experimental
MethyldopaMethyldopa may increase the hypotensive activities of BQ-123.Approved
Methylene blueMethylene blue may increase the hypotensive activities of BQ-123.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of BQ-123.Approved, Investigational
MetipranololMetipranolol may increase the hypotensive activities of BQ-123.Approved
MetolazoneMetolazone may increase the hypotensive activities of BQ-123.Approved
MetoprololMetoprolol may increase the hypotensive activities of BQ-123.Approved, Investigational
MetyrosineBQ-123 may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of BQ-123.Investigational, Withdrawn
MinaprineMinaprine may increase the hypotensive activities of BQ-123.Approved
MinoxidilMinoxidil may increase the hypotensive activities of BQ-123.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of BQ-123.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of BQ-123.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of BQ-123.Approved
MolsidomineMolsidomine may increase the hypotensive activities of BQ-123.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of BQ-123.Approved, Investigational
MuzolimineBQ-123 may increase the hypotensive activities of Muzolimine.Experimental
NadololNadolol may increase the hypotensive activities of BQ-123.Approved
NaftopidilBQ-123 may increase the hypotensive activities of Naftopidil.Investigational
NebivololNebivolol may increase the hypotensive activities of BQ-123.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of BQ-123.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of BQ-123.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of BQ-123.Approved, Investigational
NiguldipineNiguldipine may increase the hypotensive activities of BQ-123.Experimental
NilvadipineNilvadipine may increase the hypotensive activities of BQ-123.Approved, Investigational
NimodipineNimodipine may increase the hypotensive activities of BQ-123.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of BQ-123.Approved
NitrendipineNitrendipine may increase the hypotensive activities of BQ-123.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of BQ-123.Approved, Investigational
ObinutuzumabBQ-123 may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of BQ-123.Withdrawn
OlmesartanOlmesartan may increase the hypotensive activities of BQ-123.Approved, Investigational
OmapatrilatOmapatrilat may increase the hypotensive activities of BQ-123.Investigational
OxprenololOxprenolol may increase the hypotensive activities of BQ-123.Approved
PargylinePargyline may increase the hypotensive activities of BQ-123.Approved
PenbutololPenbutolol may increase the hypotensive activities of BQ-123.Approved, Investigational
PentoliniumPentolinium may increase the hypotensive activities of BQ-123.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of BQ-123.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of BQ-123.Approved
PhenelzinePhenelzine may increase the hypotensive activities of BQ-123.Approved
PheniprazinePheniprazine may increase the hypotensive activities of BQ-123.Withdrawn
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of BQ-123.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of BQ-123.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of BQ-123.Approved
PinacidilPinacidil may increase the hypotensive activities of BQ-123.Approved
PindololPindolol may increase the hypotensive activities of BQ-123.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of BQ-123.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of BQ-123.Withdrawn
Platelet Activating FactorPlatelet Activating Factor may increase the hypotensive activities of BQ-123.Experimental
PolythiazidePolythiazide may increase the hypotensive activities of BQ-123.Approved
PrazosinPrazosin may increase the hypotensive activities of BQ-123.Approved
ProcarbazineProcarbazine may increase the hypotensive activities of BQ-123.Approved, Investigational
PropranololPropranolol may increase the hypotensive activities of BQ-123.Approved, Investigational
QuinaprilQuinapril may increase the hypotensive activities of BQ-123.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of BQ-123.Approved
RamiprilRamipril may increase the hypotensive activities of BQ-123.Approved
RasagilineRasagiline may increase the hypotensive activities of BQ-123.Approved
RemikirenRemikiren may increase the hypotensive activities of BQ-123.Approved
RescinnamineBQ-123 may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of BQ-123.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of BQ-123.Approved, Investigational
RiociguatBQ-123 may increase the hypotensive activities of Riociguat.Approved
RituximabBQ-123 may increase the hypotensive activities of Rituximab.Approved
SafrazineSafrazine may increase the hypotensive activities of BQ-123.Withdrawn
SaprisartanSaprisartan may increase the hypotensive activities of BQ-123.Experimental
SelegilineSelegiline may increase the hypotensive activities of BQ-123.Approved, Investigational, Vet Approved
SelexipagSelexipag may increase the hypotensive activities of BQ-123.Approved
SildenafilSildenafil may increase the antihypertensive activities of BQ-123.Approved, Investigational
SitaxentanBQ-123 may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilSpirapril may increase the hypotensive activities of BQ-123.Approved
TadalafilTadalafil may increase the antihypertensive activities of BQ-123.Approved, Investigational
TalinololTalinolol may increase the hypotensive activities of BQ-123.Investigational
TelmisartanTelmisartan may increase the hypotensive activities of BQ-123.Approved, Investigational
TemocaprilTemocapril may increase the hypotensive activities of BQ-123.Experimental, Investigational
TerlipressinTerlipressin may increase the hypotensive activities of BQ-123.Approved, Investigational
TetrahydropalmatineBQ-123 may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalineBQ-123 may increase the hypotensive activities of Theodrenaline.Investigational
TiboloneTibolone may increase the hypotensive activities of BQ-123.Approved, Investigational
TicrynafenTicrynafen may increase the hypotensive activities of BQ-123.Withdrawn
TimololTimolol may increase the hypotensive activities of BQ-123.Approved
TolazolineTolazoline may increase the hypotensive activities of BQ-123.Approved, Vet Approved
TolonidineBQ-123 may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of BQ-123.Approved
TorasemideTorasemide may increase the hypotensive activities of BQ-123.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of BQ-123.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of BQ-123.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of BQ-123.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of BQ-123.Approved
TreprostinilTreprostinil may increase the hypotensive activities of BQ-123.Approved, Investigational
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of BQ-123.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of BQ-123.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of BQ-123.Approved, Investigational
UdenafilUdenafil may increase the antihypertensive activities of BQ-123.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of BQ-123.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of BQ-123.Investigational
ValsartanValsartan may increase the hypotensive activities of BQ-123.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of BQ-123.Approved
VincamineBQ-123 may increase the hypotensive activities of Vincamine.Experimental
VinpocetineBQ-123 may increase the hypotensive activities of Vinpocetine.Investigational
XipamideBQ-123 may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the hypotensive activities of BQ-123.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of BQ-123.Approved, Investigational, Vet Approved
ZofenoprilBQ-123 may increase the hypotensive activities of Zofenopril.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C11587
PubChem Compound
443289
PubChem Substance
347828364
ChemSpider
391535
ChEBI
2965
ChEMBL
CHEMBL314691

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingBasic ScienceHeart Failure, Unspecified1
1CompletedBasic ScienceChronic Kidney Disease (CKD) / Proteinuria1
1CompletedDiagnosticCoronary Vessels / Endothelins / Vascular Resistance1
1Enrolling by InvitationOtherHigh Blood Pressure (Hypertension) / Multiple System Atrophy (MSA) / Progressive autonomic failure1
1RecruitingBasic ScienceChronic Obstructive Pulmonary Disease (COPD) / Heart Failure, Unspecified / High Blood Pressure (Hypertension) / Pulmonary Arterial Hypertension (PAH)1
1RecruitingBasic ScienceMetabolic Syndromes1
2CompletedTreatmentMyocardial Reperfusion Injury1
2CompletedTreatmentST Elevation Myocardial Infarction (STEMI)1
2Unknown StatusTreatmentAorto-coronary Bypass Grafting / Coronary Artery Disease1
2Unknown StatusTreatmentPulmonary Hypertension (PH)1
Not AvailableCompletedNot AvailableCoronary Artery Atherosclerosis1
Not AvailableCompletedBasic ScienceCoronary Heart Disease (CHD)1
Not AvailableCompletedBasic ScienceHealthy Volunteers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.13 mg/mLALOGPS
logP1.09ALOGPS
logP0.84ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)4.04ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area189.8 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity158.59 m3·mol-1ChemAxon
Polarizability62.8 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Oligopeptides
Alternative Parents
Cyclic peptides / Macrolactams / 3-alkylindoles / Alpha amino acids and derivatives / Substituted pyrroles / Benzenoids / Tertiary carboxylic acid amides / Pyrrolidines / Heteroaromatic compounds / Secondary carboxylic acid amides
show 9 more
Substituents
Alpha-oligopeptide / Cyclic alpha peptide / Macrolactam / Alpha-amino acid or derivatives / 3-alkylindole / Indole / Indole or derivatives / Substituted pyrrole / Benzenoid / Pyrrole
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
cyclic peptide (CHEBI:2965)

Drug created on October 20, 2016 15:16 / Updated on December 01, 2017 17:31